Health related quality of life outcomes following stereotactic body radiotherapy in patients with oligo-metastatic disease: A systematic review and individual patient data meta-analysis
- Author(s)
- Barry, AS; Helou, J; Bezjak, A; Wong, R; Dawson, LA; Ringash, J; Fazelzad, R; Liu, Z; Olson, R; Palma, D; Ost, P; Siva, S; Phillips, R; Adhikari, NKJ;
- Journal Title
- Radiotherapy and Oncology
- Publication Type
- Review
- Abstract
- INTRODUCTION: Published health-related quality of life (HRQOL) outcomes are lacking in patients treated for oligo-metastatic disease (OMD). The aim of this systematic review and individual patient data meta-analysis is to determine the effect of stereotactic body radiotherapy (SBRT) on HRQOL outcomes of patients with OMD. METHODS: Studies screened included adults with extra-cranial OMD, defined as </= 5 metastases, SBRT intended as definitive treatment, and HRQOL as primary or secondary outcome. Primary outcome was change in HRQOL at 12-months from baseline in patients with OMD who received SBRT (versus not), reported as standardized mean difference (SMD). RESULTS: A total of 7556 publications were identified, four studies met inclusion criteria (2 single arm interventional studies and 2 randomised controlled trials [RCTs]), and individual patient data was available from 3 studies (175 patients). In the two RCTs, there was no SS difference in the SMD between patients who received SBRT and those that did not (0.09 [95 % CI -0.32, 0.5], P = 0.66). On meta-analysis of patients (N = 107) who received SBRT the SMDwas -0.23 (95 % CI [-0.42, -0.04], versus -0.25 (95 % CI [-0.57, 0.07]) in those who did not (N = 37) receive SBRT, demonstrating a small deterioration from baseline. CONCLUSION: In patients with OMD, there is no difference in HRQOL at 12-months from baseline between patients who received SBRT and those that did not. However, a small HRQOL deterioration was found in both groups of patients. More in-depth analysis of relevant HRQOL domains, in the setting of OMD, is required to better understand the potential impact of SBRT.
- Keywords
- Adult; Humans; *Neoplasms/radiotherapy; Quality of Life; *Radiosurgery; Health related quality of life; Metastatic directed therapies; Oligo-metastatic disease; Patient reported outcomes; Sabr; Sbrt
- Department(s)
- Radiation Oncology
- PubMed ID
- 35680076
- Publisher's Version
- https://doi.org/10.1016/j.radonc.2022.05.033
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-09-26 05:45:33
Last Modified: 2024-09-26 05:48:04